These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6283411)

  • 21. Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study.
    Nathan N; Debord J; Narcisse F; Dupuis JL; Lagarde M; Benevent D; Lachatre G; Feiss P
    Acta Anaesthesiol Belg; 1993; 44(3):77-85. PubMed ID: 8310787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Elimination kinetics and dosage of digoxin in patients in renal failure (author's transl)].
    Ohnhaus EE; Spring P; Dettli L
    Dtsch Med Wochenschr; 1974 Sep; 99(37):1797-803. PubMed ID: 4457307
    [No Abstract]   [Full Text] [Related]  

  • 23. Theophylline toxicity risks and chronic renal failure.
    Nicot G; Charmes JP; Lachatre G; Sautereau D; Valette JP; Eichler B; Leroux-Robert C
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):398-401. PubMed ID: 2793275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetics of dibekacin in patients with chronic renal impairment].
    Viotte G; Leroy A; Godin M; Fillastre JP
    Nouv Presse Med; 1982 Nov; 11(46):3414-8. PubMed ID: 7155849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacokinetics of intramuscular mezlocillin in patients with normal and impaired renal function (author's transl)].
    Brogard JM; Comte F; Kopferschmitt J; Dorner M; Lavillaureix
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):340-6. PubMed ID: 6460973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F; Floridi AG; Floridi A; Buoncristiani U
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipyrine kinetics in Nigerian women in chronic renal failure.
    Iyun AO; Tucker GT
    Afr J Med Med Sci; 1982 Mar; 11(1):7-9. PubMed ID: 6291357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.
    Chodos J; Francke EL; Saltzman M; Neu HC
    Ther Drug Monit; 1981; 3(1):71-4. PubMed ID: 6262952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The plasma turnover of 125I beta 2 microglobulin in healthy humans and patients with renal insufficiency (author's transl)].
    Vincent C; Pozet N; Revillard JP
    J Physiol (Paris); 1980; 76(8):885-7. PubMed ID: 6165821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
    Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data.
    Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Investigations on the pharmacokinetics of pentoxifylline in chronic renal failure (authors transl)].
    Schaefer K; von Herrath D; Hensel A; Grigoleit HG
    Med Klin; 1977 Feb; 72(6):204-6. PubMed ID: 840136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
    Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elimination kinetics of ceftizoxime in humans with and without renal insufficiency.
    Ohkawa M; Okasho A; Sugata T; Kuroda K
    Antimicrob Agents Chemother; 1982 Aug; 22(2):308-11. PubMed ID: 6100425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of chloroquine in renal insufficiency.
    Salako LA; Walker O; Iyun AO
    Afr J Med Med Sci; 1984; 13(3-4):177-82. PubMed ID: 6099980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of hydroxy-DL-proline-2-(14)C in the investigation of hydroxyproline metabolism in normal subjects and in patients with renal insufficiency.
    Hart W; van den Hamer CJ; van der Sluys Veer J
    Clin Nephrol; 1976 Sep; 6(3):379-87. PubMed ID: 991465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure.
    Rodondi LC; Flaherty JF; Schoenfeld P; Barriere SL; Gambertoglio JG
    Clin Pharmacol Ther; 1989 May; 45(5):527-34. PubMed ID: 2721108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.
    Ings RM; Reeves DS; White LO; Bax RP; Bywater MJ; Holt HA
    J Pharmacokinet Biopharm; 1985 Apr; 13(2):121-42. PubMed ID: 4057054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ofloxacin pharmacokinetics in renal failure.
    Couet W; Mignot A; Lefebvre M; Akbaraly J; Fourtilan J; Fillastre J; Leroy A; Humbert G
    Chemioterapia; 1987 Jun; 6(2 Suppl):313-4. PubMed ID: 3509428
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.